Afleveringen
-
In 2017 two respected Danish Scientists claimed that higher dosages of the GLP1 Semaglutide, which had been planned as a treatment for Obesity, were not supported by the Clinical trials. I look at the timing of this article and their controversial statement. I search for the missing Phase II Ozempic Clinical trials and take a look at the Phase III Ozempic Trials on Diabetics and question the small amount of weight loss found alongside the large number of side effects. I also chat to Kevin about his surprising Mounjaro weight loss journey.
Contact
Special Note
In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.
Legal and Medical Disclaimer:
The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.
Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.
Copyright
All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.
Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.
LINKS TO DOCUMENTS MENTIONED
Danish female Scientist Deadline show video
https://www.dr.dk/nyheder/indland/laegeformand-deadline-ringede-og-morgenen-efter-landede-der-et-tilbud-fra-novo
Annals of Translational Medicine Article
annals: https://atm.amegroups.org/article/view/17434/html
Ozempic Clinical Trials:
SUSTAIN 1
https://clinicaltrials.gov/study/NCT02054897?tab=results
SUSTAIN 2 clinical trial
https://clinicaltrials.gov/study/NCT01930188?term=%20NCT01930188&rank=1
SUSTAIN 3 clinical trial
https://clinicaltrials.gov/study/NCT01885208?term=NCT01885208&rank=1&tab=results
SUSTAIN 4 clinical trial
https://clinicaltrials.gov/study/NCT02128932?term=NCT02128932&rank=1
SUSTAIN 5 clinical trial
https://clinicaltrials.gov/study/NCT02305381?term=NCT02305381&rank=1
SUSTAIN 6 clinical trial - Heart Study
https://clinicaltrials.gov/study/NCT01720446?term=NCT01720446&rank=1
-
This week we look backwards in time in order to move forwards. We check out the first GLP1 drugs and take a longer look at Liraglutide which is a GLP1 found in Victoza (diabetes) and Saxenda (weightloss). We also chat to Lorrie and talk in depth about her journey on Saxenda and why she ended up choosing it over Ozempic.
Lorrie faced many challenges on her journey and I highlight three of the main ones that usually anyone faces when first going on a GLP1 medicine for weight loss. We also take a look at the lawsuits currently underway in the USA over Saxenda and how Novo Nordisk has had to pay out millions of dollars to settle, plus we take a look at the numerous lawsuits claiming gastrointestinal issues and is there any link between them and the clinical trials?
Links to Documents:
European Medicines Agency Report on Liraglutide
Australian Public Assessment Report on Liraglutide
SCALE Liragutide Clinical Study 3.0mg dosage
Korean University Study
Contact
Special Note
In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.
Legal and Medical Disclaimer:
The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.
Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.
Copyright
All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.
Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.
-
Zijn er afleveringen die ontbreken?
-
Diary of a CEO
This week I look at the previous and present CEO's of Novo Nordisk and examine their different passion projects and attitudes towards weight loss drugs. I ask the question why didn't the previous CEO push the button on the Wegovy clinical trials after many of the Ozempic clinical trials had been completed? What made him hesitate... and more importantly why did the new CEO make initiating those trials one of his first big decisions?
I look at how CEO's are paid worldwide and how Company Shares can be a larger source of income than their multi million dollar salaries. I look at the conflict of interest that often comes with awarding incentives and bonuses.
I chat with Dave Ahern from Investing for Beginners Podcast about Novo Nordisk and the meteoric rise of their share price and how Ozempic and Wegovy have driven that.
Documents Links that are mentioned in the Podcast:
Ozempic Dosage Trial
The SUSTAIN 4 Clinical Trial
2016 Novo Nordisk Annual Report
2023 Renumeration Report of Novo Nordisk
Time Article on Lars Jorgensen
Financial Times Article on Lars Jorgensen
Harvard Business Review CEO of the year article on Lars Sorensen
Contact
Special Note
In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.
Legal and Medical Disclaimer:
The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.
Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.
Copyright
All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.
Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.
-
Welcome to Investigating Ozempic.
To see the fully formed picture of the new weight loss drugs I've had to dig deep. Years of research and interviews with scientists and health professionals. This is no junior jigsaw puzzle - it's a pretty tricky one - so get on board!
This week we follow the twists... and turn over three major puzzle pieces of the hidden picture to reveal the truth behind the new weight loss drugs. We look at Government Regulators, Drug Companies and the Worldwide Obesity Epidemic.
We ask the Question: Is this potentially the Perfect Storm - Because we have never had these three events coincide before.
Is it a small rain shower or a Stage 5 hurricane? - it's anyone's guess.
Plus we take a look at what to expect from the Podcast.
Episodes will drop weekly approximately.
Contact
Special Note
In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECTS of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of advice on if these drugs are suitable for Diabetics. I am not a qualified health care professional.
Legal and Medical Disclaimer:
The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.
Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. We encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.
Copyright
All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.
Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.
-
INVESTIGATING OZEMPIC
I want to tell you how this whole whole thing started. I was in the process of writing my fifth book, researching and writing about the new weight loss drugs - in particular Ozempic and Wegovy. I was reading clinical trials and medical reports. but the further I looked the more there was to see and what I found often wasn't pretty.
Plus I couldn't believe people were not even talking about these issues...like at all. I realised pretty quickly that no one knew the full story.
I reached out to scientists, Government regulators worldwide and medical professionals to confirm what I'd found. I applied for documents through freedom of information.
We're going to start at the beginning of my journey and tell you exactly what I've found and what I think it means. We're going to attach all of the documents so you can have a look too. I'm also issuing an open invitation to the manufacturer Novo Nordisk to answer my many emails which as yet have received no answer.
If you're thinking of taking these new weight loss drugs or possibly you already are you might want to have a listen. I'm going to drop episodes weekly until all of the jigsaw pieces fall into place for you, and you too can see the totally shocking picture.
Follow our podcast called Investigating Ozempic which will be COMING SOON.
We look forward to you joining us. SUBSCRIBE to follow.
Music from #Uppbeat
https://uppbeat.io/t/philip-anderson/achievement
License code: J2HHAZ0N0WPZMQKP
DISCLAIMER:
The Investigating Ozempic and Wegovy Podcast (Investigating Ozempic) is not an alternative for good medical advice. We are not medical professionals and encourage you to talk to your own medical professional for your own healthcare needs. The podcast is an expression of honest opinion by the hosts and is not intended to defame any parties. There has been every endeavour to obtain true and authentic information in the formation of those opinions. Fair Usage Copyright has been applied.
